Staff Profile

Dr Steven Howe

Photo

Personal Profile

Name: Steven Howe Email: s.howe@ucl.ac.uk
Title: Dr Tel: +44 (0) 207 9052795
Department: ICH - Molecular Immunology Unit Fax: +44 (0) 207 9052810
Position: Senior Research Associate Address: Wolfson Centre for Gene Therapy, Molecular Immunology Unit, Institute of Child Health, 30 Guildford St, London, WC1N 1EH
Research Domain: Infection Immunology & Inflammation Web Page:  

Profile

Research Description

Lentiviral vectors based on HIV make excellent vehicles to deliver genes to both dividing and non-dividing cells. We are using this technology to study gene transfer and expression in haematopoietic stem cells to try and improve their survival in culture and to enhance stem cell transplantation treatments. Viral vectors are also being used to deliver genes for gene therapy of childhood metabolic disorders, such as Gaucher disease, and immunodeficiencies, including SCID-X1, ADA, and CGD. We are also continually trying to improve the properties of the viral vectors that we use, to improve their stability and ease of use, reduce their toxicity and enhance their efficacy.

Research Activities

Development of the enteric neuromusculature

Gene Therapy and stem cell manipulation

Novel therapies for gut disorders/diseases

Education Description

UCL Collaborators

Dr Ahad Rahim; Dr Suwan Jayasinghe; Dr Suzy Buckley; Dr Mike Hubank; Dr Richard Day; Dr Simon Waddington; Dr Simon Eaton; Dr Paolo De Coppi; Dr Nikhil Thapar; Dr Alan Burns

External Collaborators

Publications

    2012

    • Langford-Smith A, Wilkinson FL, Langford-Smith KJ, Holley RJ, Sergijenko A, Howe SJ, Bennett WR, Jones SA, Wraith JE, Merry CLR, Wynn RF, Bigger BW (2012). Hematopoietic Stem Cell and Gene Therapy Corrects Primary Neuropathology and Behavior in Mucopolysaccharidosis IIIA Mice. MOLECULAR THERAPY, 20(8), 1610 - 1621. doi:10.1038/mt.2012.82
    • Abdul-Razak HH, Rocca C, Howe SJ, Estevez JFM, Gan CHV, Roberts A, Gregory PD, Holmes MC, Kinnon C, Thrasher AJ, Yanez-Munoz RJ (2012). Correction of mouse Prkdc scid deficiency by ZFN-driven gene targeting.
    • Howe SJ, Chandrashekran A (2012). Vector systems for prenatal gene therapy: principles of retrovirus vector design and production.. Methods Mol Biol, 891, 85 - 107. doi:10.1007/978-1-61779-873-3_5
    • Alonso-Ferrero ME, Bartolovic K, Kinnon C, Mata M, Van Til NP, Howe SJ (2012). Transient manipulation of haematopoietic stem cells with integrative deficient lentiviral vectors for improved cell expansion, survival and engraftment.
    • Aitchison KL, Rahim AA, Hughes D, Kinnon C, Waddington SN, Howe SJ (2012). Developing lentiviral vectors for gene therapy of Type I Gaucher Disease.
    • Vink CA, Howe SJ (2012). Epigenetics of integration-deficient lentiviral vectors.
    • Munye MM, Howe SJ, Hart SL (2012). Towards gene therapy for primary ciliary dyskinesia.
    • Cooray S, Howe SJ, Thrasher AJ (2012). Retrovirus and lentivirus vector design and methods of cell conditioning.. Methods Enzymol, 507, 29 - 57. doi:10.1016/B978-0-12-386509-0.00003-X
    • Mohanty ST, Cairney CJ, Chantry AD, Madan S, Fernandes JA, Howe SJ, Moore HD, Thompson MJ, Chen B, Thrasher A, Keith WN, Bellantuono I (2012). A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice. STEM CELLS, 30(6), 1134 - 1143. doi:10.1002/stem.1065
    • Pantoglou J, Abdul-Razak HH, Rocca C, Howe SJ, Gregory PD, Holmes MC, Kinnon C, Thrasher AJ, Yanez-Munoz RJ (2012). Specificity of a zinc-finger nuclease targeting mouse Prkdc: preparation of samples for analysis of off-target cutting.

    2011

    • Almarza E, Zhang F, Santilli G, Blundell MP, Howe SJ, Thornhill SI, Bueren JA, Thrasher AJ (2011). Correction of SCID-X1 using an enhancerless Vav promoter.. Hum Gene Ther, 22(3), 263 - 270. doi:10.1089/hum.2010.119
    • Rocca C, Abdul-Razak HH, Estevez FJM, Guenechea G, Howe SJ, Holmes MC, Gregory PD, Thrasher AJ, Bueren JA, Yanez-Munoz RJ (2011). ZFN-driven gene targeting to correct mouse Prkdc scid deficiency. HUM GENE THER, 22(10), A44 - A44.
    • McKay TR, Rahim AA, Buckley SM, Ward NJ, Chan JK, Howe SJ, Waddington SN (2011). Perinatal gene transfer to the liver.. Curr Pharm Des, 17(24), 2528 - 2541.
    • Argyros O, Wong SP, Fedonidis C, Tolmachov O, Waddington SN, Howe SJ, Niceta M, Coutelle C, Harbottle RP (2011). Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. JOURNAL OF MOLECULAR MEDICINE-JMM, 89(5), 515 - 529. doi:10.1007/s00109-010-0713-3
    • Bartholomae CC, Arens A, Balaggan KS, Yáñez-Muñoz RJ, Montini E, Howe SJ, Paruzynski A, Korn B, Appelt JU, Macneil A, Cesana D, Abel U, Glimm H, Naldini L, Ali RR, Thrasher AJ, von Kalle C, Schmidt M (2011). Lentiviral vector integration profiles differ in rodent postmitotic tissues.. Mol Ther, 19(4), 703 - 710. doi:10.1038/mt.2011.19
    • Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, Al Ghonaium A, Bayford J, Brown L, Davies EG, Kinnon C, Thrasher AJ (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.. Sci Transl Med, 3(97), 97ra79 - . doi:10.1126/scitranslmed.3002715
    • Aitchison KL, Rahim AA, Hughes DA, Kinnon C, Waddington SN, Howe SJ (2011). Lentiviral vectors for gene therapy of Type I Gaucher Disease. HUM GENE THER, 22(10), A44 - A44.
    • Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, Al Ghonaium A, Bayford J, Brown L, Davies EG, Kinnon C, Gasper HB, Thrasher AJ (2011). Persistence of a polyclonal T-cell repertoire in patients with SCID-X1 following gene therapy. HUM GENE THER, 22(10), A42 - A42.
    • Deichmann A, Brugman MH, Bartholomae CC, Schwarzwaelder K, Verstegen MMA, Howe SJ, Arens A, Ott MG, Hoelzer D, Seger R, Grez M, Hacein-Bey-Abina S, Cavazzana-Calvo M, Fischer A, Paruzynski A, Gabriel R, Glimm H, Abel U, Cattoglio C, Mavilio F, Cassani B, Aiuti A, Dunbar CE, Baum C, Gaspar HB, Thrasher AJ, von Kalle C, Schmidt M, Wagemaker G (2011). Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy. MOL THER, 19(11), 2031 - 2039. doi:10.1038/mt.2011.178

    2010

    • Bartolovic K, Mongkoldhumrongkul N, Waddington SN, Jayasinghe SN, Howe SJ (2010). The differentiation and engraftment potential of mouse hematopoietic stem cells is maintained after bio-electrospray.. Analyst, 135(1), 157 - 164. doi:10.1039/b917813a
    • Abdul-Razak HH, Rocca C, Howe SJ, Estevez FJM, Gan CHV, Roberts A, Broadstock M, Gregory PD, Holmes MC, Kinnon C, Thrasher AJ, Yanez-Munoz RJ (2010). Towards Correction of the scid Mouse by Gene Targeting.
    • Waddington SN, Crossley R, Sheard V, Howe SJ, Buckley SM, Coughlan L, Gilham DE, Hawkins RE, McKay TR (2010). Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.. Mol Ther, 18(12), 2104 - 2111. doi:10.1038/mt.2010.174

    2009

    • Boxall SA, Cook GP, Pearce D, Bonnet D, El-Sherbiny YM, Blundell MP, Howe SJ, Leek JP, Markham AF, de Wynter EA (2009). Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells.. Bone Marrow Transplant, 43(8), 627 - 635. doi:10.1038/bmt.2008.368
    • Gjertsson I, Laurie KL, Devitt J, Howe SJ, Thrasher AJ, Holmdahl R, Gustafsson K (2009). Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Mol.Ther., 17(4), 632 - 640.
    • Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Faber K, Schwarzwaelder K, Kirsten R, Deichmann A, Ball CR, Balaggan KS, Yanez-Munoz RJ, Ali RR, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher AJ, Glimm H, von Kalle C, Saurin W, Schmidt M (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nature Medicine, 15(12), 1431 - 1U13.
    • Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike O, K C, S D, Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von KC, Gaspar HB, Thrasher AJ (2009). Insertional mutagenesis combined with acquired somatic mutations causes leukaemogenesis following gene therapy of SCID-X1 patients. Journal of Clinical Investigation, 118(9), 3143 - 3150.
    • Paruzynski A, Arens A, Gabriel R, Bartholomae C, Eckenberg R, Nowrouzi A, Scholz S, Howe S, Recchia A, Cattoglio C, Wang W, Faber K, Schwarzwaelder K, Kirsten R, Deichmann A, Ball C, Balaggan K, Yanez-Munoz R, Ali R, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher A, Glimm H, von Kalle C, Saurin W, Schmidt M (2009). Integration site analysis by non-restrictive (nr) LAM-PCR combined with optimized high-throughput sequencing. Human Gene Therapy, 20(11), 1509 - 1510.
    • Howe S, Bartolovic K, Milsom M, Thrasher A, Kinnon C (2009). Optimisation of integration-deficient lentivirus (IDLV) application in hematopoietic stem cells. Human Gene Therapy, 20(11), 1463 - 1463.
    • Himoudi N, Yan M, Bouma G, Morgenstern D, Wallace R, Seddon B, Buddle J, Eddaoudi A, Howe SJ, Cooper N, Anderson J (2009). Migratory and antigen presentation functions of IFN-producing killer dendritic cells. Cancer Res., 69(16), 6598 - 6606.
    • Paruzynski A, Gabriel R, Eckenberg R, Bartholomae CC, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Schwarzwaelder K, Kirsten R, Deichmann A, Ball CR, Balaggan KS, Yanez-Munoz RJ, Ali RR, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher AJ, Glimm H, von Kalle C, Saurin W, Schmidt M (2009). Modeling and Increasing the Genome Accessibility of Viral Integration Sites.
    • Rahim AA, Wong AM, Howe SJ, Buckley SM, costa-Saltos AD, Elston KE, Ward NJ, Philpott NJ, Cooper JD, Anderson PN, Waddington SN, Thrasher AJ, Raivich G (2009). Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther., 16(4), 509 - 520.
    • Boxall SA, Cook GP, Pearce D, Bonnet D, El-Sherbiny YM, Blundell MP, Howe SJ, Leek JP, Markham AF, de Wynter EA (2009). Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells. Bone Marrow Transplant., 43(8), 627 - 635.

    2008

    • Thornhill SI, Grassman E, Ulaganathan M, Waddington SN, Howe SJ, Van Der Loo H, Schambach A, Kinnon C, Baum C, Williams D, Thrasher AJ (2008). Self-inactivating retroviral vectors for gene therapy of SCID-X1.
    • Schwarzwaelder K, Schmidt M, Deichmann A, Howe S, Ott MG, Stein S, Siler U, Hacein-Bey-Abina S, Glimm H, Hoelzer D, Cavazzana-Calvo M, Thrasher A, Seger R, Grez M, von Kalle C (2008). The gene corrected clonal inventory in clinical gene therapy trials. Blood Cells, Molecules, and Diseases, 40(2), 66 - .
    • Buckley SM, Howe SJ, Sheard V, Ward NJ, Coutelle C, Thrasher AJ, Waddington SN, McKay TR (2008). Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther., 15(16), 1167 - 1175.
    • Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike OK, Chatters S, de RD, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von KC, Gaspar HB, Thrasher A (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukaemogenesis following gene therapy of SCID-X1 patients. Journal of Clinical Investigation, 118(9), 3143 - 3150.
    • Buckley SM, Howe SJ, Rahim AA, Buning H, McIntosh J, Wong SP, Baker AH, Nathwani A, Thrasher AJ, Coutelle C, McKay TR, Waddington SN (2008). Luciferin detection after intranasal vector delivery is improved by intranasal rather than intraperitoneal luciferin administration. Hum.Gene Ther., 19(10), 1050 - 1056.
    • Gabriel R, Paruzynski A, Eckenberg R, Bartholomae CC, Nowrouzi A, Wang W, Schwarzwaelder K, Arens A, Kirsten R, Deichmann A, Ball C, Howe SJ, Recchia A, Cattoglio C, Balaggan KS, Yanez-Munoz RJ, Ali RR, Mavilio F, Gaspar B, Thrasher A, Glimm H, von Kalle C, Saurin W, Schmidt M (2008). Comprehensive and Unbiased Integration Site Analysis in Clinical Gene Therapy.
    • Buckley SM, Howe SJ, Rahim AA, Buning H, McIntosh J, Wong SP, Baker AH, Nathwani A, Thrasher AJ, Coutelle C, McKay TR, Waddington SN (2008). Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration.. Human Gene Therapy, 19(10), 1050 - 1056.
    • Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C, Miller AD, Harbottle RP (2008). Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. GENE THER, 15(24), 1593 - 1605. doi:10.1038/gt.2008.113
    • Deichman A, Schmidt M, Abina SHB, Cavazzana-Calvo M, Schwarzwaelder K, Howe SJ, Thrasher AJ, Glimm H, Ott MG, Hoelzer D, Grez M, Seger R, Aiuti A, von Kalle CN (2008). Comparative integration site profile analysis in 5 clinical retroviral gene therapy studies. doi:10.1016/j.bcmd.2007.10.033
    • Bartholomae CC, Yanez-Munoz RJ, Balaggan KS, Howe SJ, MacNeil A, Ali RR, Thrasher AJ, von Kalle C, Schmidt M (2008). Nearly random integration site distribution in postmitotic rodent tissues transduced with lentiviral SIN-vectors. doi:10.1016/j.bcmd.2007.10.016
    • Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D, Schiedlmeier B, Sebire NJ, Gaspar HB, Kinnon C, Baum C, Thrasher AJ (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.. Mol Ther, 16(3), 590 - 598. doi:10.1038/sj.mt.6300393
    • Gabriel R, Paruzynski A, Eckenberg R, Bartholomae CC, Nowrouzi A, Wang W, Schwarzwaelder K, Arens A, Kirsten R, Deichmann A, Ball CR, Howe SJ, Recchia A, Claudia C, Balaggan KS, Yanez-Munoz RJ, Ali RR, Mavilio F, Gaspar HB, Thrasher AJ, Glimm H, von Kalle C, Saurin W, Schmidt M (2008). Assessing the genome accessibility of viral integration sites. Human Gene Therapy, 19(10), 1085 - 1085.
    • Le Deist F, Moshous D, Howe SJ, Nahum A, Kavadas F, Lavine D, Roifman CM, Fischer A (2008). Combined T and B Cell Immunodeficiencies. In Rezaei N, Aghamohammadi A, Notarangelo LD (Ed.), Primary Immunodeficiency Diseases: Definition, Diagnosis, and Management (pp. - ). : Springer.
    • Deichman A, Schmidt M, Abina SHB, Cavazzana-Calvo M, Schwarzwaelder K, Howe SJ, Thrasher AJ, Glimm H, Ott MG, Hoelzer D, Grez M, Seger R, Aiuti A, von Kalle CN (2008). Comparative integration site profile analysis in 5 clinical retroviral gene therapy studies. Blood Cells, Molecules, and Diseases, 40(2), 23 - .
    • Howe SJ, Mansour M, Brugman M, Pike-Overzet K, Hubank M, Jina N, de Ridder D, Staal F, Baum C, Kinnon C, Gaspar HB, Thrasher AJ (2008). Molecular analysis of a severe adverse event in the UKSCID-X1 gene therapy clinical trial. Human Gene Therapy, 19(4), 82 - .
    • Bartholomae CC, Yanez-Munoz RJ, Balaggan KS, Howe SJ, MacNeil A, Ali RR, Thrasher AJ, von Kalle C, Schmidt M (2008). Nearly random integration site distribution in postmitotic rodent tissues transduced with lentiviral SIN-vectors. Blood Cells, Molecules, and Diseases, 40(2), 6 - .
    • Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C, Miller AD, Harbottle RP (2008). Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector.. Gene Therapy, 15(24), 1593 - 1605. doi:10.1038/gt.2008.113
    • Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D, Schiedlmeier B, Sebire NJ, Gaspar HB, Kinnon C, Baum C, Thrasher AJ (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Molecular Therapy, 16(3), 590 - 598.
    • Thornhill SI, Grassman E, Ulaganathan M, Waddington SN, Howe SJ, Van Der Loo H, Schambach A, Kinnon C, Baum C, Williams D, Thrasher AJ (2008). Self-inactivating retroviral vectors for gene therapy of SCID-X1. Human Gene Therapy, 19(4), O15 - .
    • Howe SJ, Mansour M, Brugman M, Pike-Overzet K, Hubank M, Jina N, de Ridder D, Staal F, Baum C, Kinnon C, Gaspar HB, Thrasher AJ (2008). Molecular analysis of a severe adverse event in the UKSCID-X1 gene therapy clinical trial.

    2007

    • Abel U, Deichmann A, Bartholomae C, Schwarzwaelder K, Glimm H, Howe S, Thrasher A, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Fischer A, Jaeger D, von Kalle C, Schmidt M (2007). Real-time definition of non-randomness in the distribution of genomic events.. PLoS ONE, 2(6), e570 - .
    • Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Schambach A, Sinclair J, Kinnon C, Gaspar HB, Antoniou M, Thrasher AJ (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood, 110(5), 1448 - 1457.
    • Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B, Schmidt M, von Kalle C, Howe S, Thrasher AJ, Aiuti A, Ferrari G, Recchia A, Mavilio F (2007). Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood, 110(6), 1770 - 1778.
    • Laurie KL, Blundell MP, Baxendale HE, Howe SJ, Sinclair J, Qasim W, Brunsberg U, Thrasher AJ, Holmdahl R, Gustafsson K (2007). Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. Gene Therapy, 14(23), 1623 - 1631. doi:10.1038/sj.gt.3303021
    • Pike-Overzet K, de Ridder D, Weerkamp F, Baert MR, Verstegen MM, Brugman MH, Howe SJ, Reinders MJ, Thrasher AJ, Wagemaker G, van Dongen JJ, Staal FJ (2007). Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia, 21(4), 754 - 763.
    • Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler ML, de Ridder D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal FJ, Delabesse E, Villeval JL, Aronow B, Hue C, Prinz C, Wissler M, Klanke C, Weissenbach J, Alexander I, Fischer A, von Kalle C, Cavazzana-Calvo M (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest, 117(8), 2225 - 2232.
    • Bartholomae C, Balaggan K, Yanez-Munoz RJ, Howe SJ, MacNeil A, Ali R, Thrasher A, von Kalle C, Schmidt M (2007). Nearly random lentiviral integration site patterns observed in postmitotic rodent cells.
    • Schwarzwaelder K, Howe SJ, Schmidt M, Brugman M, Deichmann A, Glimm H, Schmidt S, Prinz C, Wissler M, King DJ, Zhang F, Parsley K, Gilmour KC, Sinclair J, Bayford J, Peraj R, de Ridder D, Pike-Ovezet K, Wagemaker G, Kinnon C, Abel U, Staal F, Gaspar HB, Thrasher AJ, von Kalle C (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.. Journal of Clinical Investigation, 117(8), 2241 - 2249. doi:10.1172/JCI31661
    • Buckley SMK, Howe SJ, Thrasher A, Baker AH, Mckay TR, Coutelle C, Waddington S (2007). The route of luciferin administration is a critical determinant of detection of pulmonary and nasal luciferase expression by in vivo bioimaging.

    2006

    • Bailey SI, Howe S, Schambach A, Bohne J, Kinnon C, Baum C, Thrasher AJ (2006). Investigating novel retroviral vectors for the treatment of SCID-X1.
    • Bartholomae CC, Deichmann A, Schmidt M, Yanez-Munoz RJ, Howe SJ, Schmidt S, Prinz C, Thrasher AJ, von Kalle C (2006). Non-random integration and clone selection by lentiviral SIN-LTR vectors..
    • Howe SJ, Schmidt M, Schwarzwaelder K, Deichmann A, Glimm H, Parsley K, Gilmour HB, Gaspar HB, Kinnon C, Thrasher AJ, Howe AJ (2006). Analysis of retroviralintegration sites in a SCID-X1 gene therapy trial.
    • Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE, Duran Y, Bartholomae C, Von Kalle C, Heckenlively JR, Kinnon C, Ali RR, Thrasher AJ (2006). Effective gene therapy with non-integrating lentiviral vectors. Nature Medicine, 12(3), 348 - 353. doi:10.1038/nm1365
    • Pike-Overzet K, de Ridder D, Weerkamp F, Baert MR, Verstegen MM, Brugman MH, Howe SJ, Reinders MJ, Thrasher AJ, Wagemaker G, van Dongen JJ, Staal FJ (2006). Gene therapy: is IL2RG oncogenic in T-cell development?. Nature, 443(7109), E5 - E7.

    2005

    • Parsley KL, Gaspar HB, Howe S, King D, Gilmour KG, Zhang F, Sinclair J, Von Kalle C, Ali RR, Kinnon C, Thrasher AJ (2005). Update on treatment of human SCID-X1 by somatic gene therapy using a pseudotyped gammaretroviral vector.
    • Yanez RJ, Balaggan KS, Smith AJ, Buch P, Howe S, MacNeilA D, Y A, P N K, C A, R R T, A J (2005). Effective Gene Therapy with Non-Integrating Lentiviral Vectors.
    • Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K, Gilmour K, King D, Howe S, Sinclair J, Hue C, Carlier F, Von Kalle C, de Saint BG, Le Deist F, Fischer A, Cavazzana-Calvo M (2005). Failure of SCID-X1 gene therapy in older patients. Blood, 105(11), 4255 - 4257.
    • Tschernutter M, Schlichtenbrede FC, Howe S, Balaggan KS, Munro PM, Bainbridge JW, Thrasher AJ, Smith AJ, Ali RR (2005). Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. GENE THER, 12(8), 694 - 701.
    • Bailey SI, Howe S, Schambach A, Bohne J, Russell DW, Baum C, Thrasher AJ (2005). Investigating novel retroviral vectors for the treatment of SCID-X1.

    2004

    • Schwarzwaelder K, Schmidt M, Howe S, Prinz C, Wissler M, Schmidt S, Deichmann A, Glimm H, Gaspar HB, Thrasher A, Von Kalle C (2004). Sustained polyclonal hematopoietic repopulation after successful SCID-X1 gene therapy by means of a non random integrating pseudotyped gammaretrovector.
    • Gaspar HB, Parsley K, Howe S, Gilmour K, Sinclair J, Barington A, Algonaim A, Davies G, Kinnon C, Thrasher A (2004). Update on treatment of human SCID-X1 by somatic gene therapy using a pseudotyped gammaretroviral vector.
    • Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. The Lancet, 364(9452), 2181 - 2187. doi:10.1016/S0140-6736(04)17590-9

    2003

    • Gaspar HB, Howe S, Thrasher AJ (2003). Gene therapy progress and prospects: gene therapy for severe combined immunodeficiency. Gene Therapy, 10(24), 1999 - 2004.
    • Howe S, Thrasher A (2003). Gene therapy for inherited immunodeficiencies. Current Hematology Reports, 2, 283 - 334.